Girentuximab Antibody
Girentuximab (G250) is a monoclonal antibody targeting carbonic anhydrase IX (CAIX) for anticancer research, particularly in uroepithelial carcinoma. It is utilized in preclinical studies, including in vivo PET imaging (e.g., ZiPUP trial) and in vitro assays, to investigate CAIX-expressing tumors.
Product Specifications
Product Name Alternative
CarbonicAnhydrase, Carbonic Anhydrase, Carbonic anhydrase, cG250, G250, WX-G250
Target
Carbonic Anhydrase
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Metabolism Research
Concentration
3.54 mg/mL
Purity
98.60% (May vary between batches)
Molecular Weight
145.55 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS2124941-01 0.1 mL
PE-Linked Polyclonal Antibody to Farnesoid X Receptor (FXR)
Sign In for Pricing
View Details MBS2124941-02 0.2 mL
PE-Linked Polyclonal Antibody to Farnesoid X Receptor (FXR)
Sign In for Pricing
View Details MBS2124941-03 0.5 mL
PE-Linked Polyclonal Antibody to Farnesoid X Receptor (FXR)
Sign In for Pricing
View Details